NewAmsterdam Pharma Co N.V. financial data

Symbol
NAMS, NAMSW on Nasdaq
Location
Gooimeer 2 35, Narrden, Netherlands
State of incorporation
Netherlands
Fiscal year end
December 31
Former names
NewAmsterdam Pharma Co B.V. (to 11/22/2022)
Latest financial report
10-Q - Q3 2024 - Nov 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 876 %
Debt-to-equity 17.4 %
Return On Equity -54.3 %
Return On Assets -46.2 %
Operating Margin -548 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 92.4M shares
Common Stock, Shares, Outstanding 92.2M shares
Entity Public Float 577M USD
Common Stock, Value, Issued 11.4M USD
Weighted Average Number of Shares Outstanding, Basic 94.8M shares +14.9%
Weighted Average Number of Shares Outstanding, Diluted 94.8M shares +14.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 33.6M USD +890%
Research and Development Expense 158M USD -17.7%
Operating Income (Loss) -184M USD +49.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -199M USD +64.7%
Income Tax Expense (Benefit) -1K USD
Net Income (Loss) Attributable to Parent -199M USD +64.7%
Earnings Per Share, Basic -2.25 USD/shares +68.4%
Earnings Per Share, Diluted -2.25 USD/shares +68.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 438M USD
Property, Plant and Equipment, Net 231K USD
Operating Lease, Right-of-Use Asset 493K USD
Assets 439M USD
Accounts Payable, Current 7.04M USD
Liabilities, Current 41.3M USD
Operating Lease, Liability, Noncurrent 266K USD
Liabilities 60.3M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax 4.42M USD
Retained Earnings (Accumulated Deficit) -466M USD
Stockholders' Equity Attributable to Parent 379M USD +14.2%
Liabilities and Equity 439M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -54.6M USD -71.4%
Net Cash Provided by (Used in) Financing Activities 198M USD +8185%
Net Cash Provided by (Used in) Investing Activities -385K USD -5400%
Common Stock, Shares Authorized 400M shares
Common Stock, Shares, Issued 92.2M shares
Common Stock, Par or Stated Value Per Share 0.12 EUR/shares
Deferred Tax Assets, Valuation Allowance 130M USD +59.6%
Deferred Tax Assets, Gross 130M USD +59.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -199M USD +64.7%
Operating Lease, Liability, Current 240K USD
Deferred Tax Assets, Operating Loss Carryforwards 75.7M USD +31%
Unrecognized Tax Benefits 0 USD
Depreciation, Depletion and Amortization 15K USD +66.7%
Deferred Tax Assets, Net of Valuation Allowance 12K USD -55.6%
Share-based Payment Arrangement, Expense 30.2M USD +48.3%